Literature Review
BPC-157 vs TB-500: Differences, and When Researchers Combine Them
Published: September 8, 2026
Updated: September 9, 2026
By the Curo Research Team
TL;DR
BPC-157 and TB-500 are two separate peptides that share a research reputation for tissue-repair work, not a shared molecule. BPC-157 is a synthetic 15-amino-acid fragment isolated from human gastric juice. TB-500, in the strict chemical sense, is the acetylated 7-amino-acid fragment Ac-LKKTETQ taken from residues 17-23 of the 43-residue protein thymosin beta-4. Their study records overlap in musculoskeletal and wound models but come from different research groups, mechanisms, and levels of human evidence. Researchers who work with both frequently pair them under the informal "Wolverine" label. Both compounds sit in Curo's research catalog, which lists BPC-157 and TB-500 separately, along with a combined BPC-157 and TB-500 research pairing, with lot documentation available through Curo's COA database.
Side-by-side comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Isolated from human gastric juice; first described in 1993 by Predrag Sikiric and colleagues at the University of Zagreb | Derived from thymosin beta-4, a G-actin-binding protein studied since the 1960s-70s; the synthetic fragment sold as TB-500 traces to work characterizing the parent protein's active region |
| Sequence length | 15 amino acids (GEPPPGKPADDAGLV) | 7 amino acids in the strict sense (Ac-LKKTETQ); the parent protein thymosin beta-4 is 43 residues |
| Fragment of | A larger ~40 kDa parent protein isolated from gastric juice, itself referred to as BPC | Thymosin beta-4, residues 17-23, N-terminal acetylated |
| Studied models | Rodent models across gastric/duodenal ulcers, tendon and ligament repair, muscle crush injury, bone defects, wound closure, and vascular growth, plus a small set of uncontrolled human reports | Full-length or recombinant thymosin beta-4 has rodent and in vitro data across dermal wound healing, corneal healing, cardiac repair, and progenitor-cell activity, along with human Phase 1 IV trials; the strict 7-residue fragment has a much smaller direct research record |
| Stability notes | Remains intact in human gastric juice for more than 24 hours, unusual for a peptide | A 2024 chromatography study found the intact fragment Ac-LKKTETQ did not enhance wound-healing activity in vitro, while a shorter metabolite, Ac-LKKTE, did |
| Regulatory status (2026) | Not FDA-approved; PCAC voted 8-6 on July 23, 2026 to recommend BPC-157 for the 503A bulk drug substances list; WADA Prohibited List, category S0 | Not FDA-approved; PCAC voted 8-6 on July 23, 2026 to recommend TB-500 for the 503A bulk drug substances list; thymosin-beta-4 and derivatives are WADA-prohibited under category S2.3 |
Where the research overlaps, and where it splits
The overlap between these two peptides is real but narrower than the "Wolverine" pairing suggests. Both have preclinical research tied to tissue repair: BPC-157's rodent literature spans gastrointestinal protection, tendon and ligament healing, muscle injury, bone defects, and wound closure. Full-length thymosin beta-4, the parent protein behind TB-500, has its own separate rodent and in vitro record in dermal wound healing, corneal repair, and cardiac cell migration. Where the two literatures meet is mostly at the level of application area (repair biology) rather than shared mechanism, shared research group, or shared molecule.
Each compound has its own profile on Curo, BPC-157: what the research record shows and TB-500: the thymosin beta-4 fragment distinction, for readers who want one side in depth. The split matters more than the overlap for anyone reading source material. BPC-157's research is concentrated in one lab lineage, the Sikiric group at the University of Zagreb, with independent replication from teams in Taiwan and at McGill University. TB-500's underlying science is split between full-length thymosin beta-4, which carries the larger and more clinically advanced record, and the short synthetic fragment Ac-LKKTETQ, which has comparatively little direct study. A 2024 analytical paper in the Journal of Chromatography B is the clearest fragment-specific data point: it measured Ac-LKKTETQ against its own metabolites and found the intact heptapeptide did not increase wound-healing activity in an in vitro assay, while the shorter fragment Ac-LKKTE did. That result is a reason to read TB-500 citations carefully rather than assume every finding about thymosin beta-4 applies equally to the fragment sold under the TB-500 name.
On the human side, the two compounds are at different points. BPC-157 has a small set of published human reports, including a 2021 retrospective chart review on knee pain, and a Phase II trial in acute hamstring strain that began recruiting in February 2026. Thymosin beta-4's clinical program has reached further, with completed and pending Phase I and Phase II trials of full-length or recombinant material, though those trials are registered under "Thymosin Beta 4," not under the TB-500 fragment name.
Why researchers combine them
Curo's combined listing for both compounds reflects a documented pattern in research use rather than a formal combination trial. Within a 2021 retrospective chart review on knee pain, a subgroup of 4 patients received BPC-157 combined with TB-500 (thymosin beta-4) by intra-articular injection, and the report noted improvement in 3 of the 4. That subgroup was not prespecified, had no control arm, and is too small to support a general conclusion. It remains the only published human data point on the combination identified in the peer-reviewed literature.
The rationale researchers describe for studying the two together is that their preclinical work covers overlapping repair processes (angiogenesis, tissue remodeling, wound closure) through different proposed mechanisms, which makes a combined research design a reasonable question even though the current evidence base for pairing them is thin. The "Wolverine" label itself is a naming convention that describes how the two are discussed together in research and community circles, not a shared body of trial evidence. The sibling article on the Wolverine stack pairing walks through that naming convention and the combined-use research in more depth.
Peptide pairings of this kind are not unique to BPC-157 and TB-500. The same combined-versus-separate question comes up with CJC-1295 and Ipamorelin, which are frequently studied together for a similar reason: distinct mechanisms researched for an overlapping application area. KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone, is sometimes discussed next to BPC-157 for the same reason, but it comes from a different parent molecule and a different literature.
Reading a certificate of analysis for each compound
A COA for either compound should confirm identity before anything else, and the identity check looks different for each.
For BPC-157, the certificate should name the compound as the 15-amino-acid sequence GEPPPGKPADDAGLV, and the LC-MS identity result should correspond to that sequence and its known molecular weight of roughly 1419.6 g/mol.
For TB-500, the identity question is more exacting, because the name covers two distinct materials in commercial and research use: the 7-amino-acid fragment Ac-LKKTETQ and full-length thymosin beta-4. A COA for a product sold as TB-500 should specify which one is in the vial, and the LC-MS result should match that stated identity rather than simply confirming "a peptide of the correct approximate mass."
From there, the same three-method standard applies to both: HPLC purity, LC-MS identity, and endotoxin testing, described in Curo's testing standard as how Curo tests every lot. The guide to verifying a certificate against a specific lot covers matching the lot number on the vial to the lot number on the published report, which is the step that ties a given certificate to the material actually received. Published, lot-specific records are searchable directly in Curo's certificate lookup tool, and the sibling article on Curo's independent testing record covers how those lot records hold up under outside review.
The same identity-first check applies to any pair discussed together, including Semax and Selank.
Regulatory status in 2026
Both compounds moved through the same regulatory event this year, and the outcome for each was structurally identical.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed BPC-157 and TB-500 as candidates for the section 503A bulk drug substances list, alongside KPV and MOTS-C. According to the FDA's own meeting record, the committee reviewed BPC-157 for an ulcerative colitis indication and TB-500 for wound healing. Coverage from STAT News reported that the panel voted 8-6, with one abstention, in favor of recommending both BPC-157 and TB-500 for the 503A list, over the objections of FDA's own career scientists, who said the available evidence did not support the move.
That vote is a recommendation, not a rule. PCAC is an advisory committee; the FDA is not bound by its votes and must still complete formal notice-and-comment rulemaking before either compound could be added to the 503A Bulks List. As of this article's regulatory refresh, no proposed rule or Federal Register notice had followed the July vote for either compound, and legal analysis published in the weeks after the meeting describes that process as typically taking many months. Neither compound is on the current 503A Bulks List, and neither is FDA-approved for any indication.
Both compounds also carry sport-anti-doping restrictions. BPC-157 sits on the WADA Prohibited List under category S0, non-approved substances, prohibited at all times. Thymosin-beta-4 and its derivatives, which covers material marketed as TB-500, are separately listed under category S2.3, Growth Factors and Growth Factor Modulators, also prohibited at all times. Enforcement of that rule is not hypothetical: USADA announced a four-year period of ineligibility for a triathlete in September 2025 involving both TB-500 and BPC-157.
None of this changes how Curo sells either compound. Both are supplied strictly for laboratory research, governed by Curo's research use only policy, which is separate from the FDA compounding review, the WADA sport rules, and the trial registry status described above.
FAQ
Is BPC-157 or TB-500 better for tendon repair research?
Both have rodent-model data touching tendon and connective-tissue repair, through different proposed mechanisms. BPC-157's tendon research includes an Achilles tendon transection model with biomechanical and histological outcomes. TB-500's tendon-relevant record sits mostly within the broader thymosin beta-4 literature rather than the strict 7-amino-acid fragment. Neither compound has a head-to-head tendon trial against the other, so "better" is not a question the current literature answers directly.
Does research pairing BPC-157 with TB-500 mean the combination is proven to work better than either alone?
No. The main published human data point on the combination is a 4-patient subgroup within a larger retrospective chart review, with no control arm and no prespecified design. Researchers studying the pairing are working from overlapping preclinical application areas, not from a completed combination trial.